Last reviewed · How we verify
Medigen Vaccine Biologics Corp. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
4 Phase 3
4 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| EV71vac | EV71vac | phase 3 | Inactivated viral vaccine | Enterovirus 71 (EV71) | Immunology / Infectious Disease | |
| GC FLU Quadrivalent | GC FLU Quadrivalent | phase 3 | Inactivated influenza vaccine | Immunology / Infectious Disease | ||
| Envacgen® | Envacgen® | phase 3 | Recombinant protein subunit vaccine | Immunology / Infectious Disease | ||
| MVC-COV1901 | MVC-COV1901 | phase 3 | Protein subunit vaccine | SARS-CoV-2 spike protein | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 4
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Novavax · 2 shared drug classes
- Sinovac Biotech Co., Ltd · 2 shared drug classes
- Green Cross Corporation · 2 shared drug classes
- Novartis · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Sanofi Pasteur, a Sanofi Company · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Brigham and Women's Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Medigen Vaccine Biologics Corp.:
- Medigen Vaccine Biologics Corp. pipeline updates — RSS
- Medigen Vaccine Biologics Corp. pipeline updates — Atom
- Medigen Vaccine Biologics Corp. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medigen Vaccine Biologics Corp. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medigen-vaccine-biologics-corp. Accessed 2026-05-18.